Structure−Activity Relationships of Pregabalin and Analogues That Target the α<sub>2</sub>-δ Protein

Thomas R. Belliotti(Pfizer (United Kingdom)), Thomas Capiris(Pfizer (United Kingdom)), I. Victor Ekhato(Pfizer (United Kingdom)), Jack J. Kinsora(Pfizer (United Kingdom)), Mark J. Field(Pfizer (United Kingdom)), Thomas G. Heffner(Pfizer (United Kingdom)), Leonard T. Meltzer(Pfizer (United Kingdom)), Jacob B. Schwarz(Pfizer (United Kingdom)), Charles P. Taylor(Pfizer (United Kingdom)), Andrew Thorpe(Pfizer (United Kingdom)), Mark G. Vartanian(Pfizer (United Kingdom)), Lawrence D. Wise(Pfizer (United Kingdom)), Ti Zhi-Su(Pfizer (United Kingdom)), Mark L. Weber(Pfizer (United Kingdom)), David J. Wustrow(Pfizer (United Kingdom))
Journal of Medicinal Chemistry
February 17, 2005
Cited by 209

Abstract

Pregabalin exhibits robust activity in preclinical assays indicative of potential antiepileptic, anxiolytic, and antihyperalgesic clinical efficacy. It binds with high affinity to the alpha(2)-delta subunit of voltage-gated calcium channels and is a substrate of the system L neutral amino acid transporter. A series of pregabalin analogues were prepared and evaluated for their alpha(2)-delta binding affinity as demonstrated by their ability to inhibit binding of [(3)H]gabapentin to pig brain membranes and for their potency to inhibit the uptake of [(3)H]leucine into CHO cells, a measure of their ability to compete with the endogenous substrate at the system L transporter. Compounds were also assessed in vivo for their ability to promote anxiolytic, analgesic, and anticonvulsant actions. These studies suggest that distinct structure activity relationships exist for alpha(2)-delta binding and system L transport inhibition. However, both interactions appear to play an important role in the in vivo profile of these compounds.


Related Papers

No related papers found

Powered by citation graph analysis